Skip to main content
. 2016 Jun 9;11(6):e0156200. doi: 10.1371/journal.pone.0156200

Fig 4. Modulation of B-cell activation signals during Peg-IFN-α therapy.

Fig 4

Patients with CHB infection were treated with nucleos(t)ide analog alone (open circles, n = 11–14) or together with Peg-IFN-α (black circles, n = 7–9). (A,B) Plasma levels of BAFF and APRIL. (C,D) Plasma levels of soluble CD26 and soluble CD30. The gray area represents the period of Peg-IFN-α administration. Bars represent median. P values were calculated using the Wilcoxon test (straight lines) or the Mann-Whitney test (dashed lines). * p<0.05, ** p<0.01, *** p<0.001.